Each year more people will receive a vision-threatening diagnosis due to aging and lifestyle factors. Our robust research and development approach is anchored in improving the standards of care across multiple disease areas to make a meaningful difference for patients.
Our research, focused on unmet needs, fuels an innovative pipeline of treatments that seek to preserve and protect vision and prevent blindness. Our research interests include:
Improving standards for all
Bridging our understanding of biological processes and the genetic basis of human disease to accelerate ophthalmic drug discovery.
Finding new approaches
Leading innovation in long-acting therapeutic approaches via mechanism of action, sustained-release formulations or gene therapy to reduce the treatment burden.
Collaboration in innovation
Working with colleagues across AbbVie to seize the scientific opportunity of innovation within oncology, immunology and neuroscience through knowledge of common disease pathways.
Applying state-of-the-art imaging modalities to monitor disease progression and therapeutic intervention to accelerate the translation of bench science to the clinic.
Joining forces with innovative partners that complement our strengths, capabilities and commitments to eye care, including our work in chronic retinal diseases with REGENXBIO.